Moderna announced a new $140 million investment in its onshore manufacturing facilities and bringing manufacturing capabilities to its Norwood, Massachusetts Moderna Technology Center (MTC), expanding its U.S.-based drug product manufacturing.¹

"By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.," said Stéphane Bancel, chief executive officer at Moderna. "As an American company committed to building and producing in America, we are proud to strengthen our domestic footprint while bringing meaningful new jobs to the community."

Construction is already underway at the MTC and is expected to be completed during the first half of 2027.¹ According to a report from Reuters, the expansion project is set to generate hundreds of skilled biomanufacturing jobs.

Why did Moderna invest $140 into its onshore manufacturing capabilities?

Prior to its investment, Moderna would rely on outside partners to handle its fill-finish stage of drug product manufacturing, holding the potential for setbacks in expenses, timing, and efficiency. With Moderna’s investment into self-sufficiency in this area, it opens the door to new capabilities, including complete control over the entire production process.¹

Additionally, MTC’s expansion reflects Moderna's ongoing investment in its U.S.-based infrastructure, along with its commitment to building a drug product manufacturing platform with the ability of supporting its pipeline of mRNA vaccines and therapeutics. The investment also helps improve connection within Moderna’s domestic mRNA manufacturing network.

What is the Moderna Technology Center?

Announced back in September 2016, Moderna planned to make its MTC a state-of-the-art clinical manufacturing facility, manufacturing a range of messenger RNA (mRNA) based drugs and vaccines, such as Covid-19 vaccines, for good laboratory practice (GLP) toxicology studies, and Phase I and II clinical studies.² Construction of the building was completed in early 2018, including a $110 million investment, and generated more than 200 jobs since its opening.²

The facility offers state-of-the-art integrated end-to-end process facilities, including spaces for good manufacturing practice (GMP) manufacturing, plasmid manufacturing, pre-clinical operations and testing, quality control labs, development labs, a cancer vaccine unit, a warehouse, and maintenance and administrative offices.²

MTC performs all manufacturing activities, ranging from raw material production to active pharmaceutical ingredients (APIs), formulation, and now filling and finish, at one location, producing up to 40 batches of GMP mRNA a year.²

The building is also home to all quality and infrastructure services, as well as includes a collaborative open plan office with amenities. The site also houses Moderna’s personalized cancer vaccine (PCV) unit for individual supply batches of mRNA for cancer vaccines.²

In 2019 the facility’s capabilities were recognized by the International Society for Pharmaceutical Engineering and was awarded with the Facility of the Future award.²

Sources

1. Moderna to complete US mRNA manufacturing network with $140 million investment Reuters November 19, 2025 https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-complete-us-mrna-manufacturing-network-with-140-million-investment-2025-11-19/
2. Moderna Therapeutics Clinical Manufacturing Facility, Massachusetts, USA Pharmaceutical Technology August 2, 2022 https://www.pharmaceutical-technology.com/projects/moderna-manufacturing-facility-norwood/?cf-view